Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Universiteitsplein 1, B-2610 Wilrijk, Belgium.
Multidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, B-2650 Edegem, Belgium.
Int J Mol Sci. 2021 Feb 11;22(4):1807. doi: 10.3390/ijms22041807.
Even though cervical cancer is partly preventable, it still poses a great public health problem throughout the world. Current therapies have vastly improved the clinical outcomes of cervical cancer patients, but progress in new systemic treatment modalities has been slow in the last years. Especially for patients with advanced disease this is discouraging, as their prognosis remains very poor. The pathogen-induced nature, the considerable mutational load, the involvement of genes regulating the immune response, and the high grade of immune infiltration, suggest that immunotherapy might be a promising strategy to treat cervical cancer. In this literature review, we focus on the use of PD-1 blocking therapy in cervical cancer, pembrolizumab in particular, as it is the only approved immunotherapy for this disease. We discuss why it has great clinical potential, how it opens doors for personalized treatment in cervical cancer, and which trials are aiming to expand its clinical use.
尽管宫颈癌在一定程度上是可以预防的，但它仍然是全世界一个重大的公共卫生问题。目前的治疗方法极大地改善了宫颈癌患者的临床预后，但近年来新的系统治疗方法的进展较为缓慢。特别是对于晚期疾病患者来说，这令人沮丧，因为他们的预后仍然非常差。病原体诱导的性质、相当大的突变负荷、参与调节免疫反应的基因以及高度的免疫浸润，表明免疫疗法可能是治疗宫颈癌的一种有前途的策略。在这篇文献综述中，我们重点关注 PD-1 阻断疗法在宫颈癌中的应用，特别是 pembrolizumab，因为它是唯一被批准用于该疾病的免疫疗法。我们讨论了它为什么具有巨大的临床潜力，它如何为宫颈癌的个性化治疗开辟道路，以及哪些试验旨在扩大其临床应用。
